Baxter International Inc. (BAX)
Baxter International Inc. is a global healthcare company specializing in medical products and services, including dialysis, intravenous solutions, and biopharmaceuticals. Founded in 1931, the company focuses on supporting patient care through innovative therapies and medical devices across hospitals, clinics, and homes worldwide.
Dividend History
Investors can expect a dividend payout of $0.17 per share, scheduled to be distributed in 11 days on October 1, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 1, 2025 | $0.17 | 2025-08-29 | 2025-08-29 |
| July 1, 2025 | $0.17 | 2025-05-30 | 2025-05-30 |
| April 1, 2025 | $0.17 | 2025-02-28 | 2025-02-28 |
| January 2, 2025 | $0.17 | 2024-11-29 | 2024-11-29 |
| October 1, 2024 | $0.29 | 2024-08-30 | 2024-08-30 |
Dividends Summary
- Baxter International Inc. has issued 80 dividend payments over the past 21 years
- The most recent dividend was paid 81 days ago, on July 1, 2025
- The highest dividend payed out to investors during this period was $0.582 per share
- The average dividend paid during this period was $0.29 per share.
Company News
The global infusion pump market is expected to grow from $13.12 billion in 2024 to $23.13 billion by 2032, driven by rising chronic disease prevalence, technological innovations, and increased healthcare infrastructure.
Baxter International reported strong Q1 2025 results, with adjusted EPS and sales exceeding guidance and analyst estimates. The company also raised its 2025 guidance, citing strength in its Medical Products & Therapies and Healthcare Systems & Technologies segments.
Baxter International Inc. reported better-than-expected Q2 2024 earnings, with adjusted EPS of 68 cents beating the consensus estimate. Revenue also topped expectations, driven by growth across the company's business segments. The company provided positive guidance for Q3 and full-year 2024.
Morgan Stanley downgraded Baxter International's stock from Equalweight to Underweight, citing concerns over the company's ability to meet its margin goals, particularly after its acquisition of Hillrom. The firm lowered its price target for Baxter to $30 from $39, reflecting a more conservative outlook on the company's mid-term earnings.
